Tocilizumab – Page 70 – Communicable Diseases Research

Acute Kidney Injury in COVID-19 Pneumonia: A Single-Center Experience in Bahrain

Infectious Disease

Published on 2020-08-122022-10-31
Journal: Cureus [Category] COVID-19,

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm

Article

Published on 2020-08-062022-10-04
Journal: Nature Communications [Category] MERS, 임상, 치료법, 치료제,

[키워드] Acute inflammation addition Analysis Antimicrobial responses antiviral immune responses attenuate CD8 cell population cellular cellular and molecular Computational biology and bioinformatics contribute COVID-19 COVID-19 patient COVID-19 patients Cytokine storm Cytokine storms dataset distribution excessive inflammatory response humoral identify IL-6 Immune cell immune cells immune profiling immunosuppressive drug infected with SARS-CoV-2 Inflammation Inflammatory cytokine Inflammatory response interleukin-6 monocyte Monocytes and macrophages Patient plasma B cell provide receptor reveal robust severe COVID-19 patient single-cell single-cell analysis Single-cell RNA sequencing Stage subpopulation T cells therapeutic effect Tocilizumab treat Treatment
[DOI] 10.1038/s41467-020-17834-w PMC 바로가기 [Article Type] Article

Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?

COVID-19를 포함한 인간 코로나바이러스 감염의 면역병리학적 낙진 이해: 류마티스 전문의의 길을 건너게 될까요?

Review

Published on 2020-08-012022-09-11
Journal: International journal of rheumatic diseases [Category] MERS, 진단, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Anakinra antibody antiphospholipid antibodies antiviral agent Antiviral agents autoantibodies Autoimmune Autoimmunity catastrophic cellular entry clinical trials Comparisons coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus infection COVID-19 COVID-19 infection Critical critical patients cross cytokine Cytokine storm develop disease-modifying anti-rheumatic drug effective Efficacy fatal disease Gender HCQ Hydroxychloroquine hydroxychloroquine (HCQ) IFN Immunomodulatory agents immunopathological in sight include individual Infection interferon interferons lupus erythematosus male management mechanism mechanism of action metabolic syndrome Older age pandemic patients with COVID-19 recent reported respiratory rheumatic disease Rheumatic diseases risk SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 sight Signaling SLE syndrome systemic lupus erythematosus systemic lupus erythematosus (SLE). Tocilizumab Treatment Trigger triggers Type I IFN type I interferon type I interferons understanding Vaccine versed
[DOI] 10.1111/1756-185X.13909 PMC 바로가기 [Article Type] Review

COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature

Review article

Published on 2020-08-012022-10-05
Journal: Critical Reviews in Oncology/Hematology [Category] SARS, 치료제,

[키워드] ACE2angiotensin-converting enzyme 2 AIFAItalian Medicines Agency (Agenzia Italiana del Farmaco) androgen receptor signaling inhibitors angiotensin-converting enzyme 2 antineoplastic drugs ARSIandrogen receptor signaling inhibitors article Cancer cancer patient checkpoint inhibitors Chemotherapy Clinical practice clinical trial Colchicine conducted Corona Virus Disease Course COVID COVID 19 COVID-19 COVID-19 pandemic COVID-19corona virus disease CPIcheckpoint inhibitors CYPcytochrome P450 cytochrome P450 Dipeptidyl peptidase 4 disease disease-modifying antirheumatic drugs DMARDsdisease-modifying antirheumatic drugs DPP4Dipeptidyl peptidase 4 drug drug interaction Future highlight HIV-1human immunodeficiency virus Human immunodeficiency virus IL6Interleukin 6 Immunotherapy Inconclusive Interaction interleukin 6 Italian Medicines Agency (Agenzia Italiana del Farmaco) literature review oncologist positive provide Result ruxolitinib systematic review targeted therapy therapy Tocilizumab Treatment treatments for COVID-19
[DOI] 10.1016/j.critrevonc.2020.102991 [Article Type] Review article

Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer

COVID-19 관련 sHLH에서 IL-6 및 JAK/STAT 억제 요법 결합, 잠재적 게임 체인저

Case Reports

Published on 2020-08-012022-09-12
Journal: British Journal of Haematology [Category] MERS, SARS, 진단,

[키워드] Abstract Combined COVID cytokine Cytokine storm IL-6 JAK/STAT ruxolitinib secondary haemophagocytic lymphohistiocytosis Severe COVID sHLH therapy Tocilizumab
[DOI] 10.1111/bjh.16966 PMC 바로가기 [Article Type] Case Reports

To Toci or Not to Toci for COVID-19: Is That Still the Question?

Editorial

Published on 2020-07-312023-07-02
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS,

[키워드] coronavirus COVID COVID-19 immunomodulatory SARS-CoV-2 Tocilizumab
[DOI] 10.1093/cid/ciaa1133 PMC 바로가기 [Article Type] Editorial

Treatment Options for COVID-19: A Review

Medicine

Published on 2020-07-312022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] acute respiratory syndrome analyses antimicrobial agent antimicrobial agents Antiviral antiviral agent caused chloroquine/hydroxychloroquine coronavirus COVID-19 COVID-19 pandemic detect disease Drug repurposing effective Efficacy Evidence global pandemic globe Google Scholar higher infectivity highlight identify Immunoglobulin in vitro study Ivermectin lower mortality MERS-CoV morbidity and mortality multicenter option outbreak pandemic Pandemics Randomized controlled trial regimen Remdesivir retrospective review SARS-CoV SARS-CoV-2 searched single antiviral agent Tocilizumab Treatment Trial Vaccine virus widespread
[DOI] 10.3389/fmed.2020.00480 PMC 바로가기 [Article Type] Medicine

Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS

Case Report

Published on 2020-07-272022-10-30
Journal: Medicina [Category] COVID-19, SARS,

[키워드] acute respiratory distress acute respiratory distress syndrome (ARDS) Antiviral approach ARDS BMI C-reactive protein calibrated Case report cells clinical condition Coagulation Combination Combined COVID-19 COVID-19 patient Cytokines decrease dropped Dyspnea effort Endothelium Fever hypoxia IL-6 IL-6 receptor immune-mediated inflammation Immunotherapy IMV Inflammation Inflammatory interfere interleukin-6 Intubated Invasive mechanical ventilation Laboratory limit male management monoclonal antibody Neutrophil-to-lymphocyte ratio NIV NLR non-invasive ventilation outcomes Oxygenation P/F P/F ratio PaO Pathogenesis Patient Pneumonia prone positioning Rapid reducing reported response suggested syndrome TCZ therapy Tocilizumab treated Treatment ventilatory strategy with COVID-19 worsening
[DOI] 10.3390/medicina56080377 PMC 바로가기 [Article Type] Case Report

COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis

Review

Published on 2020-07-212022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS,

[키워드] ACE2 addition Affect angiotensin Anti-inflammatory drugs antibody attenuate binding CD4+ T cell CD8+ clinical trial common cold contribute coronavirus 2 correlated country CoV COVID-19 infection develop diffusion drug Efficacy enzymatic activity Frequency functional healthcare identify immune immune system immunization in viral infect Infection involved measure Neutralizing antibodies outbreak outcome pandemic Patient Perspective Pneumonia positive prevention receptor Replication resources respiratory review SARS-CoV2 SARS-CoV2 infection severe respiratory syndrome severity single-stranded RNA virus Symptom the disease Tocilizumab Transcription Treatment turn Vaccine virus
[DOI] 10.3390/ijms21145145 PMC 바로가기 [Article Type] Review

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

Review

Published on 2020-07-202023-07-02
Journal: Pulmonology [Category] SARS,

[키워드] AIFA, Agenzia Italiana del Farmaco ARDS, acute respiratory distress syndrome coronavirus COVID-19 COVID-19, Coronavirus disease 2019 CPAP, continuous positive airway pressure CRS, CAR-T cell-induced cytokine release syndrome GCA, Giant cell arteritis ICTRP, International Clinical Trials Registry Platform IDSA, Infectious Diseases Society of America IMV, invasive mechanical ventilation NIH, U.S. National Institutes of Health NIV, Noninvasive mechanical ventilation pJIA, Pediatric juvenile idiopathic arthritis Pneumonia RA, Rheumatoid arthritis SARS-CoV-2 SIMIT, Italian Society of Infectious and Tropical disease sJIA, Juvenile idiopathic arthritis TNF, Tumor Necrosis Factor Tocilizumab WHO, World Health Organization
[DOI] 10.1016/j.pulmoe.2020.07.003 PMC 바로가기 [Article Type] Review